azacitidine celgene
celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
thalidomide celgene 50mg capsules
celgene ltd - thalidomide - capsule - 50mg
refludan
celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - antithrombotic agents - anticoagulation in adult patients with heparin-induced thrombocytopenia type ii and thromboembolic disease mandating parenteral antithrombotic therapy.the diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.
revlimid 2.5mg capsules
celgene ltd - lenalidomide - capsule - 2.5mg
abraxane 100mg powder for suspension for infusion vials
celgene ltd - paclitaxel albumin - powder for suspension for infusion - 100mg
thalidomide celgene 50 mg hard capsules
neopharm ltd - thalidomide - hard capsule - thalidomide 50 mg - thalidomide - multiple myeloma : 1. for the treatment of multiple myeloma after failure of standars therapies. 2. thalidomide celgene 50 mg hard capsules in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma. 3. thalidomide celgene in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma > or = 65 years or ineligible for high dose chemotherapy. erythema nodosum leprosum: 4. for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalidomide is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. it is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence.בקשה לעדכון משטר מינון 4/2/2020
vidaza 100mg powder for suspension for injection vials
celgene ltd - azacitidine - powder for suspension for injection - 100mg
otezla 30mg tablets
celgene ltd - apremilast - tablet - 30mg
otezla tablets treatment initiation pack
celgene ltd - not applicable
revlimid
celgene limited, a bristol myers squibb company - lenalidomide 10mg; - capsule - 10 mg - active: lenalidomide 10mg excipient: capsugel yellow 4035 capsule blue-green 6579 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.